US Approves First New Type of Flu Drug in 2 Decades

Associated Press |

TRENTON, N.J. (AP) — U.S. health regulators have approved the first new type of flu drug in two decades.

Wednesday's approval of Xofluza for people age 12 and older comes ahead of the brunt of this winter's flu season.

Xofluza (Zoh-FLEW'-zeh) is a pill that can reduce flu symptoms after one just dose. It developed by the Roche Group and Japan's Shionogi.

It works about as well as Tamiflu, Roche's older flu treatment, which is also available in cheaper generic versions.

Health officials have said an estimated 80,000 Americans died of flu and its complications last winter, the disease's highest death toll in at least four decades.

Roche's  (RHHBY) Genentech unit plans to launch Xofluza within a few weeks. It will cost $150 without insurance.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
RHHBY Roche Holding Ltd ADR (Sponsored) 31.01 0.03 0.10 997,250

Comments

Emerging Growth

Alliance Growers Corp

Alliance Growers Corp is a Canada based diversified cannabis company. The company is primarily focused on the development of Cannabis Botany Centres in Canada.